BRIEF published on 03/23/2026 at 07:35, 7 months 9 days ago Sensorion poursuit son développement en thérapie génique pour la surdité Thérapie Génique SENS-501 Surdité Congénitale Audiogene SENS-601
BRIEF published on 03/23/2026 at 07:35, 7 months 9 days ago Sensorion continues its development in gene therapy for deafness Gene Therapy Congenital Deafness Audiogene Sense-501 Sense-601
BRIEF published on 03/23/2026 at 07:35, 7 months 9 days ago Mises à jour de Sensorion sur l'essai Audiogene et les progrès du GJB2-GT Essais Cliniques Thérapie Génique Sensorion Perte Auditive SENS-601
PRESS RELEASE published on 03/23/2026 at 07:30, 7 months 9 days ago Informations privilégiées / Autres communiqués Sensorion publie les données à six mois de l’essai clinique de Phase 1/2 Audiogene pour SENS-501 et poursuit le développement clinique du GJB2-GT (SENS-601) vers une première administration chez l’homme Essai Clinique Thérapie Génique Sensorion Surdité GJB2-GT
BRIEF published on 03/18/2026 at 07:35, 7 months 14 days ago Sensorion Reports 2025 Results and Corporate Updates Financial Results Gene Therapy Sensorion Hearing Loss Sanofi Investment
BRIEF published on 03/18/2026 at 07:35, 7 months 14 days ago Sensorion publie ses résultats 2025 et les dernières nouvelles de l'entreprise Résultats Financiers Thérapie Génique Sensorion Perte Auditive Investissements Sanofi
PRESS RELEASE published on 03/18/2026 at 07:30, 7 months 14 days ago Inside Information / News release on accounts, results Sensorion reports full-year 2025 results, provides corporate update, and announces release of annual report. Key milestones in gene therapies for hearing loss. Financial highlights and future expectations highlighted Financial Highlights Full-year Results Sensorion Gene Therapies Future Milestones
PRESS RELEASE published on 03/18/2026 at 07:30, 7 months 14 days ago Informations privilégiées / Communiqué sur comptes, résultats Sensorion publie ses résultats annuels 2025, met à jour sa feuille de route et annonce la publication du rapport annuel, avec des avancées significatives dans les thérapies géniques pour la perte auditive Résultats Annuels Bilan Financier Thérapies Géniques Sensorion Perte Auditive
BRIEF published on 02/17/2026 at 07:35, 8 months 12 days ago Sensorion annonce des changements dans sa direction Sensorion Changement Direction Thérapie Auditive Financement Sanofi Pipeline Médical
BRIEF published on 02/17/2026 at 07:35, 8 months 12 days ago Leadership Transition at Sensorion amid Strategic Focus on Hearing Loss Therapies Biotechnology Gene Therapy Leadership Change Sensorion Hearing Loss
Published on 10/30/2026 at 23:35, 2 days 4 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 4 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 9 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 12 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/01/2026 at 10:35, 17 hours 48 minutes ago Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 23 hours 23 minutes ago 2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 11 hours ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 5 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 23:00, 2 days 5 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 2 days 5 hours ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
